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Aberrant expression of antigen presentation machinery
(APM) has been closely associated with more aggressive
tumors and may inhibit the therapeutic response to
T-cell based immunotherapies. Furthermore, the selective
pressure of immunotherapies may select for resistant
clones that down regulate expression of APM as means
of therapeutic resistance. This report characterizes a
microfluidic assay for the screening and serial assessment
of APM in circulating tumor cells (CTCs) from patients
with advanced renal cell carcinoma and prostate cancer.
Cell surface expression of MHC class I is identified in
both renal cell and prostate cancer CTCs. Gene expres-
sion analysis for components of APM in CTCs is also
validated using quantitative RT-PCR. The results of these
studies suggest a unique CTC biomarker that may serve
as a predictive and pharmacodynamic biomarker for use
in clinical trials with T-cell based immunotherapies.
Future studies will focus on the development of assays
for markers of resistance to checkpoint inhibitors and
expression of tumor associated antigens.
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